Fanconi Anemia: New Advances in Genetic Studies

Author: Universitat Autonoma de Barcelona
Published: 2011/03/03 - Updated: 2022/05/19
Category Topic: Medical Research News - Academic Publications

Page Content: Synopsis - Introduction - Main

Synopsis: Fanconi anaemia is a rare hereditary disease which mainly affects the bone marrow and causes it to produce less blood cells. The predominant genetic mutation originated in Europe thousands of years ago and later migrated to America. The Canary island of La Palma and Brazil, with a high prevalence of the disease, were two areas in which the mutation spread widely.

Introduction

New advances in genetic studies of Fanconi anemia patients - Published online in Blood, the journal of the American Society of Hematology. The predominant genetic mutation originated in Europe thousands of years ago and later migrated to America. The Canary island of La Palma and Brazil, with a high prevalence of the disease, were two areas in which the mutation spread widely.

Main Content

Fanconi anaemia is a rare hereditary disease which mainly affects the bone marrow and causes it to produce less blood cells. Treatment includes transplanting healthy blood stem cells from the bone marrow or umbilical cord of a compatible donor, if possible, a relative. Unfortunately, few patients can find a healthy and compatible donor. It is however a crucial disease to biomedical research since it is associated with vital functions such as embryonic development, blood production and genetic predisposition to cancer.

A consortium of thirty-two researchers worldwide, led by Dr. Jordi Surralles, professor of the Department of Genetics and Microbiology at Universitat Autanoma de Barcelona (UAB) and member of the Center for Biomedical Network Research on Rare Diseases (CIBERER), genetically and clinically characterized almost all Spanish patients suffering from Franconi anaemia, a rare disease impacting one in every 500,000 persons and which is characterized by severe anemia in children, congenital malformations and a high predisposition to cancer.

A hundred people in Spain suffer from Fanconi anaemia; 80% of these present mutations in the FANCA gene. In the research, 90% of these patients were studied, as well as patients in Brazil, Mexico, Argentina, Peru, United States, United Kingdom, Portugal, Germany, Pakistan, and Nigeria.

The research includes characterization of over 130 pathogenic mutations in the FANCA gene, present in two of every three cases in almost all the countries analyzed, as well as the study of the origin and world distribution of some of the most frequent mutations. The mutation predominating in Spain and in the rest of the countries is an ancestral mutation of Indo-European origin which spread throughout Europe thousands of years ago and which reached America across the Atlantic, producing founder effects in areas such as La Palma, with a high prevalence of the disease, and Brazil, where half of all patients share the same gene mutation.

Finally, researchers analyzed the effects of the genetic mutations and their clinical impacts. Results indicate that these mutations provoke the absence or dysfunction of FANCA protein, which prevent it from reaching the cell nucleus and activating a DNA repair pathway necessary for genomic stability. This in turn brings about cell death - producing anaemia and abnormal tissue functions - or causes them to develop into tumors. For this reason, the study of genes involved in Fanconi anaemia is essential to understand the factors which protect the general population from cancer.

Researchers verified that the fact that mutation produces protein absence or dysfunction does not determine the clinical evolution of anaemia or the severity of the malformation syndrome.

Dr. Jordi Surralles highlights the importance of the study carried out given that results will have significant applications in the diagnosis, prognosis, and evolution of this rare disease. For example, several of the mutations described in the article served to carry out prenatal and even pre-implant diagnoses follow by the selection of healthy and compatible embryos, with the aim of using blood from the umbilical cord for bone marrow transplants to cure siblings.

Participating in the research were eleven hospitals in Spain and Portugal, two of which are UAB-affiliated hospitals (Sant Pau Hospital and Vall d'Hebron University Hospital) and several national and international research and university centers: CIEMAT (Center for Energetic, Environmental and Technological Research), CNIO (National Cancer Research Center), CIBERER, University of Würzburg, The Rockefeller University, New York, and VU University Medical Center, Amsterdam.

Through its Genome Instability and DNA Repair Group, directed by Dr. Jordi Surralles, UAB has become a worldwide leader in research carried out into Fanconi anaemia. Recently, it has contributed greatly to the further understanding of genetic mechanisms involved in the disease, to the improvement of diagnoses and advances in new therapies, both independently and with the collaboration of institutions such as CIEMAT, CIBERER and CRMB (Center of Regenerative Medicine in Barcelona).

Reference

Origin, functional role and clinical impact of Fanconi anaemia FANCA mutations. Castella M, Pujol R, Callen E, Trujillo JP, Casado JA, Gille H, Lach FP, Auerbach AD, Schindler D, Benitez J, Porto B, Ferro T, Muaoz A, Sevilla J, Madero L, Cela E, Belendez C, Diaz de Heredia C, Olive T, Sanchez de Toledo J, Badell I, Torrent M, Estella J, Dasi A, Rodriguez-Villa A, Gomez P, Barbot J, Tapia M, Molines A, Figuera A, Bueren JA, Surralles J. Blood. 2011 Jan 27.

Attribution/Source(s): This quality-reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally authored by Universitat Autonoma de Barcelona and published on 2011/03/03, this content may have been edited for style, clarity, or brevity.